Core Insights - Fortress Biotech, Inc. and its subsidiary Cyprium Therapeutics announced the sale of Cyprium's Rare Pediatric Disease Priority Review Voucher for gross proceeds of $205 million, marking a significant corporate transaction for both entities [1][2] Financial Impact - Fortress expects to receive over $100 million from the PRV sale, which will enhance its financial flexibility for business development and advancing its portfolio [2] - Cyprium is eligible for tiered royalties on net sales of ZYCUBO® and up to approximately $128 million in aggregate sales milestones from Sentynl Therapeutics [3] Product Development and Approvals - Fortress' portfolio has achieved three FDA approvals in the last 15 months for products Emrosi™, UNLOXCYT™, and ZYCUBO® [2] - ZYCUBO® was approved by the FDA on January 12, 2026, for the treatment of Menkes disease in pediatric patients [4] Corporate Structure and Strategy - Cyprium is a majority-owned subsidiary of Fortress, focusing on novel therapies for Menkes disease and related disorders [4] - Fortress operates with a model aimed at acquiring and advancing biopharmaceutical assets to enhance long-term shareholder value through various revenue streams [5]

Core Viewpoint - Fortress Biotech, Inc. and its subsidiary Cyprium Therapeutics announced the sale of a Rare Pediatric Disease Priority Review Voucher for $205 million, indicating strong corporate execution and potential for profitability in the near future [1][3]. Group 1: Transaction Details - Cyprium entered into a definitive asset purchase agreement to sell its PRV for gross proceeds of $205 million upon closing [1]. - The PRV was issued following the FDA approval of ZYCUBO on January 12, 2026, which was developed by Cyprium and is intended for the treatment of Menkes disease [2]. - Cyprium will receive tiered royalties on net sales of ZYCUBO and up to $129 million in development and sales milestones from Sentynl Therapeutics [2]. Group 2: Company Achievements - The approval of ZYCUBO is a significant milestone for patients with Menkes disease, showcasing Cyprium's ability to execute value-generating transactions [3]. - Fortress has received three FDA approvals in the last 15 months for its products, including Emrosi™, UNLOXCYT™, and ZYCUBO, positioning the company for potential profitability this year [3]. - Cyprium is advancing AAV-ATP7A Gene Therapy toward clinical development, which aims to provide additional treatment options for Menkes disease [3][4]. Group 3: Company Background - Cyprium Therapeutics focuses on developing therapies for Menkes disease and related copper metabolism disorders, having established a partnership with the Eunice Kennedy Shriver National Institute of Child Health and Human Development [4]. - Fortress Biotech is an innovative biopharmaceutical company with a diverse portfolio, including eight marketed prescription products and multiple development programs across various therapeutic areas [5][6].